•
December 14, 2022

ASH22 Reaction - TRIANGLE

•
December 14, 2022

ASH22 Reaction - TRIANGLE

Author
Back to Blog

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for AutologousStem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network  

‍

Abstract #1: Martin Dreyling presented efficacy and safety results of the P3 TRIANGLE trial in 870 younger patients with previously untreated, advanced stage II-IV mantle cell lymphoma(MCL).

‍

The TRIANGLE trial assessed:

  • Standard treatment (R-CHOP/R-DHAP + ASCT) (Arm A);
  • vs addition of ibrutinib to Arm A regimen (Arm A+I);
  • vs standard treatment with ibrutinib but without ASCT (Arm I);
  • followed by 2 years ibrutinib maintenance in arms A+I and I

‍

Results:

  • Overall response (OR) rates: 94% (arm A) vs 98% (combined arms A+I/I)
  • Complete remission (CR) rates: 36% (arm A) vs 45% (combined arms A+I/I)
  • 3-year failure-free survival (FFS): 86% (arm I) vs 88% (arm A+I) vs 72% (arm A)
  • 3-year OS: 92% (arm I) vs 91% (arm A+I) vs 86% (arm A)
  • Rituximab maintenance did not substantively change results
  • No substantial differences in grade 3-5 AEs when adding ibrutinib to standard treatment or between the two ASCT-containing arms
  • Substantially more grade 3-5 AEs in A+I arm as compared to arms A or I during maintenance
  •  

‍

ASH22

‍

Thought leader reactions were positive, with several interpreting the results to mean that they could forego ASCT during induction with ibrutinib without compromising on OS and FFS, and thus considering it as new standard first-line therapy for younger patients with MCL.

‍

Graham
Santhosh
Fernando
Thomas
Remy

The favourable AE profile and lack of treatment related mortality (TRM) with ibrutinib induction without ASCT was also of interest.

‍

Aaron

A few oncologists were concerned about the cost of ibrutinib maintenance in lower and middle income countries (LMIC)

‍

Pallawi
Dr Luis

Summary: Thought leaders are excited enough by these results that many consider induction with ibrutinib without ASCT to be a new first-line treatment younger patients with previously untreated, advanced stage II-IV MCL. More study will need to be done to confirm the role of ASCT in this population, and in localities where ibrutinib might be costly to use.

‍

Opus

Synthesis powered by Opus Strategy, LLC.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022

@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!

Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Other Posts
Blog Posts
•
August 9, 2023

From Passion to Profession: Meet LARVOL’s VP Sales, Linh Nguyen

In this edition of our ongoing series "In The Spotlight", we're excited to chat with Linh Nguyen, the VP Sales at LARVOL. With a passion for healthcare and a commitment to making a difference in the oncology field, Linh has been a vital part of our team for over six years. Let’s get to know Linh better through her own words, exploring her journey, motivations, and the personal interests that round out her life.

Read more
Blog Posts
•
August 9, 2023

Our Shift to the Metaverse: A Conversation with CEO Bruno Larvol

In 2020, as most of the business world wrestled with the transition to remote work, my company chose an alternate approach. As Founder and CEO, I began pushing for a very different but equally culture-shifting change. I moved our corporate headquarters to the metaverse, and we’re never looking back.

Read more
Blog Posts
•
August 9, 2023

The Latest in ADCs: Precision Tools in Cancer Treatment

The battle against cancer is shifting, with Antibody-Drug Conjugates (ADCs) leading a revolution in precision therapy. These biological innovators are changing the game for many patients, offering a glimmer of hope in an often daunting prognosis. Here’s a closer look at the promising world of ADCs and how they're transforming cancer care.

Read more
Blog Posts
•
August 9, 2023

LARVOL's CONF Case Study: An In-depth Q&A with Angela Kaya, Director of Publications & Scientific Communications at PMV Pharma

Navigating the busy world of pharmaceutical conferences can be a daunting task, filled with endless sessions, abstracts, and updates to keep track of. This is where LARVOL CONF comes into play – offering a simple, yet powerful way to organize and manage conference information effectively.

Read more
Larvo logo footer

Solutions

Insights

Company

LARVOL & SEMPER TIGRIS are registered trademarks in the European Community
Copyright © LARVOL 2023
Privacy PolicyKOL Privacy PolicyAcceptable Use Policy
Waves